Developer of Liquid Biopsy, Blood-Based Tests Hires Seasoned Biopharma Executive to Support the Next Phase of Growth BALTIMORE and PALO ALTO, Calif. , Aug. 26, 2024 /PRNewswire/ -- Today, DELFI Diagnostics, Inc.
, developer of accessible blood-based liquid biopsy tests that deliver a new way to enhance early cancer detection, is announcing the expansion of its leadership team with the appointment of Thomas Russo as its Chief Financial Officer (CFO). Mr. Russo most recently served as CFO of Icosavax, Inc.
, where he helped guide the clinical-stage biopharmaceutical company through a pivotal growth period from its initial public offering through its acquisition by AstraZeneca for a total equity value of up to $1.1 billion . "Tom has a proven track record of supporting innovators in healthcare, and his combined expertise across biopharma, finance, commercialization, and the investment community makes him an incredible addition to our growing team of industry visionaries," said Susan Tousi , CEO of DELFI Diagnostics.
"DELFI is poised to revolutionize cancer screening to better support providers and patients. Tom's appointment expands our capabilities to ensure fiscal excellence, drive adoption at scale, and fulfill the company's potential." Mr.
Russo brings extensive expertise in finance, operations, and equity research for public biopharma companies, including CFO roles at Icosavax, Inc. and Assembly Biosciences, Inc., and senior finance and commercial operations roles at Gilead S.